Control Trial of Intermittent Hemodialysis With Regional Citrate VS Priming Heparin With Predilution in Patients at Risk of Bleeding (ROBIN)
Randomized Controlled Trial of Intermittent Hemodialysis With Regional Citrate Anticoagulation Versus Systemic Low Dose Heparin Anticoagulation in Patients at Risk of Bleeding in Nephrology Intensive Care Unit
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nîmes, France, 30029
- CHU Nîmes
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The patient has been correctly informed.
- The patient must have given his/her informed and signed consent.
- The legal guardian or trusted-person of an adult under guardianship must have given their informed and signed consent.
- The patient has health insurance coverage via the French social security system.
- The patient is at least 18 years old.
- The patient is at bleeding risk; the bleeding risk is defined by the clinical situation and according to predefined clinical situations (before or after surgery or biopsy, hemorrhage).
- The patient requires an intermittent hemodialysis in a nephrology ICU setting.
Exclusion Criteria:
- The patient is participating in, or has participated in over the past three months, another interventional trial.
- The patient is in an exclusion period determined by a previous study.
- The patient is under judicial protection.
- The parents (or legal guardian) of the patient refuse to sign the consent.
- It is impossible to correctly inform the patient/parents (or legal guardian) of the patient (language barrier).
- Contraindication to heparin treatment.
- Indication of continuous dialysis in ICU.
- Pregnancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Control
|
receive intermittent hemodialysis (Frésenius 4008) with blood flow at least of (200 ml/min) with double vascular access, biocompatible membrane dialyzer, low dose non fractionated heparine (5000 UI initially) and predilution with 25 mls/min dialysate
|
|
Experimental: Prometheus System
|
intermittent hemodialysis using Prometheus System with blood flow at least of 200 ml/min with double vascular access, biocompatible membrane dialyzer
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Duration of intermittent hemodialysis between groups
Time Frame: End of intermittent hemodialysis session (average 4 hours)
|
Minutes
|
End of intermittent hemodialysis session (average 4 hours)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hemodialysis treatment adequacy
Time Frame: End of intermittent hemodialysis session (average 4 hours)
|
KT/V value
|
End of intermittent hemodialysis session (average 4 hours)
|
|
Transmembrane pressure between groups
Time Frame: End of intermittent hemodialysis session (average 4 hours)
|
End of intermittent hemodialysis session (average 4 hours)
|
|
|
Blood aspect in the extracorporeal treatment circuit
Time Frame: End of intermittent hemodialysis session (average 4 hours)
|
Clotting phenomena
|
End of intermittent hemodialysis session (average 4 hours)
|
|
Occurrence of hemorrhage
Time Frame: Hour 12
|
Yes/no
|
Hour 12
|
|
Occurrence of metabolic disorders (hypocalcemia, metabolic alkalose)
Time Frame: Hour 12
|
Yes/no
|
Hour 12
|
|
Occurance of unexpected complications (almost none recorded in the literature)
Time Frame: End of intermittent hemodialysis session (average 4 hours)
|
Yes/no
|
End of intermittent hemodialysis session (average 4 hours)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Olivier Moranne, MD, CHU Nîmes
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2016/NIMAO2/OM-01
- 2018-A00141-54 (Other Identifier: ANSM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.